myeloproliferative

By Targets:	Apoptosis (5) DNA Alkylator/Crosslinker (1) JAK (6) Phosphodiesterase (PDE) (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146186

JAK2 JH2 binder-1	JAK	Cancer
JAK2 JH2 binder-1 (compound 11) is a potent and selective JAK2 JH2 binder, with a K_d of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research .

HY-16398

Pipobroman	DNA Alkylator/Crosslinker	Cancer
Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .

HY-16020

AC-430 hydrobromide	JAK	Cancer
AC-430 hydrobromide (example 1) is a potent JAK2 inhibitor. AC-430 hydrobromide can be used for the research of myeloproliferative disorders and cancer .

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-10409

Fedratinib Maximum Cited Publications 31 Publications Verification TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-10409A

Fedratinib hydrochloride hydrate Maximum Cited Publications 31 Publications Verification TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-124727

ZT55	JAK Apoptosis	Cancer
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC₅₀ value of 0.031 μM. ZT55 inhibits the proliferation of JAK2 ^V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia .

HY-B0523

Anagrelide	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library	2687 Compounds compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 2687 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

2687 Compounds compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 2687 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.	Product Name	Target	Research Area

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

Species:	Human (3) Mouse (2)
Tag:	His (5)
Source:	HEK293 (4) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70637

	TPO/Thrombopoietin Protein, Human (HEK293, His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Human	HEK293
	TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.

HY-P700155AF

	Animal-Free TPO/Thrombopoietin Protein, Human (His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Human	E. coli
	TPO/Thrombopoietin Protein, a lineage-specific cytokine, significantly influences megakaryocyte proliferation and maturation, particularly in late developmental stages from committed progenitor cells. It emerges as a potential major physiological regulator, underscoring its crucial role in the intricate orchestration of circulating platelets and emphasizing its importance in megakaryocyte biology and platelet formation. Animal-Free TPO/Thrombopoietin Protein, Human (His) is the recombinant human-derived animal-FreeTPO/Thrombopoietin protein, expressed by E. coli , with N-His labeled tag. The total length of Animal-Free TPO/Thrombopoietin Protein, Human (His) is 174 a.a., with molecular weight of ~19.6 kDa.

HY-P70637A

	TPO/Thrombopoietin Protein, Human (HEK293, C-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Human	HEK293
	TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.

HY-P70686

	TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Mouse	HEK293
	TPO/Thrombopoietin Protein, a lineage-specific cytokine, crucially regulates megakaryocyte proliferation and maturation, acting in the late stages of development from committed progenitor cells. Recognized as a major physiological regulator, TPO significantly influences circulating platelets, emphasizing its importance in the intricate process of platelet formation. TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, His) is the recombinant mouse-derived TPO/Thrombopoietin protein, expressed by HEK293 , with N-6*His labeled tag. The total length of TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, His) is 335 a.a., with molecular weight of 80-110 kDa.

HY-P70686A

	TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, C-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Mouse	HEK293
	TPO/Thrombopoietin Protein, a lineage-specific cytokine, crucially regulates megakaryocyte proliferation and maturation, acting in the late stages of development from committed progenitor cells. Recognized as a major physiological regulator, TPO significantly influences circulating platelets, emphasizing its importance in the intricate process of platelet formation. TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, C-His) is the recombinant mouse-derived TPO/Thrombopoietin protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, C-His) is 335 a.a., with molecular weight of approximately 75 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P82496

Thrombopoietin Receptor Antibody (YA2241)

MPL; TPOR; Thrombopoietin receptor; TPO-R; myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110
WB Human, Mouse, Rat

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.